| Mr Billy Christopher Sferner, | |
|
1950 N Okmulgee, Okmulgee, OK 74447-6534 | |
| (918) 756-7700 | |
| (918) 756-3347 |
| Full Name | Mr Billy Christopher Sferner |
|---|---|
| Gender | Male |
| Speciality | Counselor |
| Location | 1950 N Okmulgee, Okmulgee, Oklahoma |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154698926 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Billy Christopher Sferner, 1950 N Okmulgee, Okmulgee, OK 74447-6534 Ph: (918) 756-7700 | Mr Billy Christopher Sferner, 1950 N Okmulgee, Okmulgee, OK 74447-6534 Ph: (918) 756-7700 |
News Archive
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced it has reacquired Pliaglis development and marketing rights for the U.S., Canada and Mexico.
An international research team led by Queen's University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.
MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.
EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).
› Verified 4 days ago
Leslie Lynn Crow, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 W 7th St, Suite 102, Okmulgee, OK 74447 Phone: 918-758-1910 Fax: 918-756-1270 | |
Frank Wayne Mayhew, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1805 S Wood Dr, Okmulgee, OK 74447 Phone: 918-756-9250 | |
Mrs. Naomi Hankins, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1803 S Wood Dr, Okmulgee, OK 74447 Phone: 918-756-9250 | |
Miss Gay Lynn Peterson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 323 W 6th St, Okmulgee, OK 74447 Phone: 918-756-9250 | |
Mrs. Thomasine L. Fife, LADC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 W 7th St Ste 102, Okmulgee, OK 74447 Phone: 918-758-1930 | |
Hilary Megan Snyder, MASTER OF ARTS IN CH Counselor Medicare: Not Enrolled in Medicare Practice Location: 1950 N Okmulgee, Okmulgee, OK 74447 Phone: 918-756-7700 Fax: 918-756-3347 | |
Ladonna Kay Shadlow, CBHCM, BA Counselor Medicare: Not Enrolled in Medicare Practice Location: 114 N Grand Ave Ste 418, Okmulgee, OK 74447 Phone: 918-227-2016 |